Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Nov 18, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell

This study looked at the effectiveness of autologous stem cell transplantation after their first remission for patients with high-risk diffuse large B-cell lymphoma. The study concluded that patients who received autologous stem cell transplantation had better outcomes than those who did not.

Some background

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. First-line treatment for DLBCL is R-CHOP chemotherapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone). Autologous stem cell transplantation (auto-SCT; using stem cells from the patient’s own body) is used as second line therapy.

Auto-SCT is considered very effective. However auto-SCT is most often used later in a patient’s treatment strategy. More research is needed to determine the effectiveness of auto-SCT after first remission. 

Methods & findings

The medical records of 272 patients were reviewed. 208 patients were treated with R-CHOP alone. 64 patients were treated with R-CHOP followed by auto-SCT. The average length of follow up was 37 months.

The progression free survival rate (time from treatment to disease progression) was better for patients who received auto-SCT than those who did not. The difference was not statistically significant.

94 patients had high-risk DLBCL. All of these patients achieved a complete response (no detectable cancer) after R-CHOP therapy. 41 of these high risk patients received auto-SCT. 53 patients did not. Of the high-risk patients, patients who had auto-SCT treatment had significantly better 3-year progressive free survival rates (59.6%) compared to patients who did not receive auto-SCT (32.1%). Patients treated with auto-SCT also had significantly better 3-year overall survival rates (time from treatment to death from any cause) (74.5%) compared to patients who did not receive auto-SCT (50.4%). 

The bottom line

The authors concluded that patients with high-risk diffuse large B-cell lymphoma have better outcomes when treated with R-CHOP followed by autologous stem cell transplantation compared to R-CHOP alone.

Published By :

Oncotarget

Date :

Sep 22, 2017

Original Title :

Prognostic analysis of DLBCL patients and the role of upfront ASCT in high-intermediate and high-risk patients.

click here to get personalized updates